In collaboration with organic chemists, we discovered a new promising approach to treat the inflammatory component of glaucoma. This could help us generate new glaucoma drugs complementary to existing therapies and protecting the vision of patients more effectively.
One new compound with the potential to become a novel drug for diabetic retinopathy by protecting the nerve cells in the eye.
A medical device for patients with diabetes that would allow the physician to assess the risk for diabetic retinopathy, and would allow the patient to continuously monitor the disease’s progress and therapy success through a simple blood test requiring only a finger prick blood sample.
Two new potential drugs to treat the dry form of AMD , one new potential drug to treat diabetic retinopathy caused by Type 1 diabetes and two new potential drugs to treat glaucoma are in advanced stages of development.
Two new drug delivery approaches for established wet AMD drugs that would eliminate the need for frequent injections in the eye.
A medical device for AMD patients and those with occlusion of their retinal blood vessels which could ultimately eliminate lengthy, invasive procedures.
A new drug delivery approach for established glaucoma drugs that would eliminate the need for daily eye drops– specifically, we are looking to turn glaucoma drugs into a slow release version administered only a few times per year.
A medical device that will reduce the pressure in the eye of patients for which conventional glaucoma drug treatment failed and surgery is the only option.